The escalation of antimicrobial resistance in pathogenic bacteria is an ongoing serious global threat to human health. Yet only a limited number of novel vaccines and antimicrobial agents with advanced mechanisms of action are available to combat these microbes effectively. Consequently, the situation demands that experimental designs should go beyond the search for novel classes of antibiotics and include testing and advocating alternative therapies that can cure multidrug-resistant infections. A well-tolerated and appropriate combinational therapy using nanoparticle delivery systems can be a breakthrough in the treatment of those life-threatening infections. Besides, the availability of advanced genomic characterization technologies has led to a new paradigm in the expansion of new vaccine development and the enhanced efficacy of currently available drugs and vaccines.
Hence, in combination with optimal antibiotics, nanoparticle drug delivery systems have been progressively exploited to increase drug accumulation at the infection site, minimize toxicity, and protect the antibiotic from peripheral degradation. Moreover, nanoparticle drug delivery systems advocate the delivery of antigenic protein vaccines, thus stimulating humoral and cellular immunity. Consequently, a wide range of diverse compounds and therapeutic drugs can, therefore, be encapsulated and delivered.
On the other hand, pan-genome analyses and comparative genomics using next-generation sequencing technologies allow a detailed understanding of intra- and inter-species antigen variability and distribution. As a result, comprehensive multi-genome analyses will support the identification of potential vaccine candidates against highly variable pathogens.
This Research Topic aims to assess current and prospective research on the use of nanotechnology in combination therapy to treat infectious disease and to overcome antibiotic resistance. We also welcome research that utilises genomic analysis to better understand how these technologies can be utilised to combat microbe variability and distribution. We welcome original research and review articles that cover, but are not limited to, the following areas:
1. New research into combinatorial approaches against pathogenic bacteria, in which two or more therapies are used in combination to overcome their individual limitations, which are delivered by nanoparticle drug delivery systems.
2. Advances in the development of nanoparticle drug delivery systems to overcome antibiotic resistance.
3. Applying whole-genome sequencing of pathogenic bacteria, identifying possible antigens expressed, and facilitating the recognition of key potential vaccine candidates for use in combinational therapies.
The escalation of antimicrobial resistance in pathogenic bacteria is an ongoing serious global threat to human health. Yet only a limited number of novel vaccines and antimicrobial agents with advanced mechanisms of action are available to combat these microbes effectively. Consequently, the situation demands that experimental designs should go beyond the search for novel classes of antibiotics and include testing and advocating alternative therapies that can cure multidrug-resistant infections. A well-tolerated and appropriate combinational therapy using nanoparticle delivery systems can be a breakthrough in the treatment of those life-threatening infections. Besides, the availability of advanced genomic characterization technologies has led to a new paradigm in the expansion of new vaccine development and the enhanced efficacy of currently available drugs and vaccines.
Hence, in combination with optimal antibiotics, nanoparticle drug delivery systems have been progressively exploited to increase drug accumulation at the infection site, minimize toxicity, and protect the antibiotic from peripheral degradation. Moreover, nanoparticle drug delivery systems advocate the delivery of antigenic protein vaccines, thus stimulating humoral and cellular immunity. Consequently, a wide range of diverse compounds and therapeutic drugs can, therefore, be encapsulated and delivered.
On the other hand, pan-genome analyses and comparative genomics using next-generation sequencing technologies allow a detailed understanding of intra- and inter-species antigen variability and distribution. As a result, comprehensive multi-genome analyses will support the identification of potential vaccine candidates against highly variable pathogens.
This Research Topic aims to assess current and prospective research on the use of nanotechnology in combination therapy to treat infectious disease and to overcome antibiotic resistance. We also welcome research that utilises genomic analysis to better understand how these technologies can be utilised to combat microbe variability and distribution. We welcome original research and review articles that cover, but are not limited to, the following areas:
1. New research into combinatorial approaches against pathogenic bacteria, in which two or more therapies are used in combination to overcome their individual limitations, which are delivered by nanoparticle drug delivery systems.
2. Advances in the development of nanoparticle drug delivery systems to overcome antibiotic resistance.
3. Applying whole-genome sequencing of pathogenic bacteria, identifying possible antigens expressed, and facilitating the recognition of key potential vaccine candidates for use in combinational therapies.
